{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:30:17Z","timestamp":1764783017497,"version":"build-2065373602"},"reference-count":134,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.critrevonc.2007.06.007","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T08:57:35Z","timestamp":1185958655000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura"],"prefix":"10.1016","volume":"65","author":[{"given":"Zeping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2007.06.007_bib1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.critrevonc.2004.12.004","article-title":"Multi-dysfunctional pathophysiology in ITP","volume":"54","author":"Zhou","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib3","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopha.2004.04.006","article-title":"Rituximab in autoimmune diseases","volume":"58","author":"Virgolini","year":"2004","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1651-2227.2005.tb01887.x","article-title":"Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease","volume":"94","author":"Zeller","year":"2005","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","article-title":"The incidence of idiopathic thrombocytopenic purpura in adults increases with age","volume":"94","author":"Frederiksen","year":"1999","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2007.06.007_bib7","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00043426-200312001-00008","article-title":"Idiopathic thrombocytopenic purpura in adults","volume":"25","author":"Provan","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404008415","article-title":"Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy","volume":"6","author":"Andersson","year":"2004","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1054\/blre.2001.0178","article-title":"Novel approaches to refractory immune thrombocytopenic purpura","volume":"16","author":"Bussel","year":"2002","journal-title":"Blood Rev"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib10","first-page":"91","article-title":"Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients","volume":"27","author":"Bussel","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.med.56.082103.104644","article-title":"Management of adult idiopathic thrombocytopenic purpura","volume":"56","author":"Cines","year":"2005","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4065\/79.4.504","article-title":"Management of immune thrombocytopenic purpura in adults","volume":"79","author":"Stasi","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/pbc.20980","article-title":"Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia","volume":"47","author":"Crow","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1416","article-title":"Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells","volume":"12","author":"Siragam","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1532\/IJH97.04173","article-title":"Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura","volume":"81","author":"Kojouri","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2006.02013.x","article-title":"Management of patients with refractory immune thrombocytopenic purpura","volume":"4","author":"George","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib17","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.7326\/0003-4819-126-4-199702150-00007","article-title":"Therapy for adults with refractory chronic immune thrombocytopenic purpura","volume":"126","author":"McMillan","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/146532401753174133","article-title":"CAMPATH-1H in the treatment of autoimmune cytopenias","volume":"3","author":"Marsh","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.10413","article-title":"Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)","volume":"74","author":"Narang","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2003-06-2167","article-title":"Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura","volume":"103","author":"Kuwana","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/blre.2001.0169","article-title":"Pathophysiology of platelet destruction in immune (idiopathic) thrombocytopenic purpura","volume":"16","author":"McFarland","year":"2002","journal-title":"Blood Rev"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.21307\/immunohematology-2019-562","article-title":"Serologic aspects of treating immune thrombocytopenic purpura using intravenous Rh immune globulin","volume":"17","author":"Savasman","year":"2001","journal-title":"Immunohematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib24","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood-2004-11-4547","article-title":"B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model","volume":"106","author":"Dunussi-Joannopoulos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib25","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jbspin.2004.04.007","article-title":"Novel concepts and treatments for autoimmune disease: ten focal points","volume":"71","author":"Sibilia","year":"2004","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib28","first-page":"213","article-title":"Signalling pathways in B cells: implications for autoimmunity","volume":"305","author":"Dorner","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/14728222.9.3.431","article-title":"B cells as a therapeutic target in autoimmune diseases","volume":"9","author":"Park","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopaenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib31","first-page":"3","article-title":"Crossroads of B cell activation in autoimmunity: rationale of targeting B cells","volume":"77","author":"Dorner","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib32","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.177.7.4481","article-title":"B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation","volume":"177","author":"Yan","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib33","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.176.4.2654","article-title":"B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice","volume":"176","author":"Tian","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.61.10.863","article-title":"Treating human autoimmune disease by depleting B cells","volume":"61","author":"Looney","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1084\/jem.192.4.475","article-title":"B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation","volume":"192","author":"Moulin","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0955-3886(00)00004-7","article-title":"Comparison of platelet immunity in patients with SLE and with ITP","volume":"22","author":"Lazarus","year":"2000","journal-title":"Transfus Sci"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1191\/0961203302lu309oa","article-title":"Disturbances in peripheral blood B cell subpopulations in autoimmune patients","volume":"11","author":"Potter","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2141.2006.06431.x","article-title":"High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura","volume":"136","author":"Emmerich","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib41","first-page":"18","article-title":"B cell tolerance and autoimmunity","volume":"2","author":"Tsubata","year":"2000","journal-title":"Rev Immunogenet"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib42","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2741\/2217","article-title":"B cell receptor editing in tolerance and autoimmunity","volume":"12","author":"Azulay-Debby","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08916930500123959","article-title":"B cell abnormality and autoimmune disorders","volume":"38","author":"Tsubata","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib44","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4049\/jimmunol.174.4.1775","article-title":"B cell selection and susceptibility to autoimmunity","volume":"174","author":"Grimaldi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib45","first-page":"1","article-title":"Determinations of B cell fate in immunity and autoimmunity","volume":"8","author":"Noelle","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","article-title":"CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes","volume":"14","author":"Hultin","year":"1993","journal-title":"Cytometry"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib47","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib49","first-page":"1763","article-title":"Clinical status and optimal use of rituximab for B-cell lymphomas","volume":"12","author":"McLaughlin","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib50","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"66","author":"Cvetkovic","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib51","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/38.11.1150","article-title":"Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma","volume":"38","author":"Protheroe","year":"1999","journal-title":"Eumatology (Oxford)"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib52","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1191\/0961203303lu449cr","article-title":"Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy","volume":"12","author":"Weide","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib54","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib55","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib56","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJM200410283511820","article-title":"Rituximab for rheumatoid arthritis","volume":"351","author":"Okamoto","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib57","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-05-0554","article-title":"Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib58","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"(Chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","author":"Vega","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib59","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib60","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib61","first-page":"176","article-title":"The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes","volume":"91","author":"Golay","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2005.1.329","article-title":"Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy","author":"Friedberg","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib63","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"(Monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib64","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib65","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"(Anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib66","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","article-title":"Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells","volume":"83","author":"Stanglmaier","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib67","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib68","doi-asserted-by":"crossref","first-page":"pe30","DOI":"10.1126\/stke.2412004pe30","article-title":"Empowering targeted therapy: lessons from rituximab","volume":"2004","author":"Olszewski","year":"2004","journal-title":"Sci STKE"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib69","first-page":"5137","volume":"61","author":"Alas","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/ar751","article-title":"B cells as a therapeutic target in autoimmune disease","volume":"5","author":"Goronzy","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib72","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib74","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","author":"Provan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib75","first-page":"1209","article-title":"Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura","volume":"95","author":"Aggarwal","year":"2002","journal-title":"South Med J"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib76","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1196\/annals.1361.111","article-title":"Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency","volume":"1051","author":"Carbone","year":"2005","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib77","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib78","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","article-title":"Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature","volume":"26","author":"Santos","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib79","first-page":"3968","article-title":"Resistant Idiopathic Thrombocytopenic Purpura\u2014treatment with Rituximab","volume":"108","author":"Saouli","year":"2006","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib80","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/1076029606293439","article-title":"Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report","volume":"12","author":"Latifzadeh","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.thj.6200148","article-title":"Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab","volume":"3","author":"Cohen","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.1112","article-title":"Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma","volume":"67","author":"Shvidel","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib83","first-page":"215","article-title":"Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura","volume":"87","author":"Delgado","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ajh.20243","article-title":"Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases","volume":"78","author":"Koulova","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib85","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-133-4-200008150-00011","article-title":"Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease","volume":"133","author":"Ratanatharathorn","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib86","first-page":"1273","article-title":"Rituximab in the treatment of refractory autoimmune cytopenias in adults","volume":"90","author":"Narat","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib87","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1067\/S0022-3476(03)00446-3","article-title":"Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura","volume":"143","author":"Bengtson","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib88","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1034\/j.1600-0609.2001.066006408.x","article-title":"Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia","volume":"66","author":"Faurschou","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib89","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00431-004-1417-x","article-title":"Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia","volume":"163","author":"Pusiol","year":"2004","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib90","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00431-005-1631-1","article-title":"Rituximab treatment in refractory idiopathic thrombocytopenic purpura in children","volume":"164","author":"Roganovic","year":"2005","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib91","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1440-1754.2005.00641.x","article-title":"Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura","volume":"41","author":"Moschovi","year":"2005","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib92","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2004.05243.x","article-title":"Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura","volume":"127","author":"Ahmad","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib93","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ajh.20270","article-title":"Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab","volume":"78","author":"Weitz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib94","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00277-005-1094-5","article-title":"Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease","volume":"84","author":"Trelinski","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/10245330410001714248","article-title":"Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura","volume":"9","author":"Lalayanni","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib96","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg469","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus","volume":"43","author":"ten Cate","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib97","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib98","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000077570","article-title":"Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis","volume":"111","author":"Thude","year":"2004","journal-title":"Acta Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib99","first-page":"262","article-title":"Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura","volume":"61","author":"Riksen","year":"2003","journal-title":"Neth J Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.10309","article-title":"Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab","volume":"73","author":"Hensel","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib101","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00431-004-1498-6","article-title":"Rituximab in children with idiopathic thrombocytopenic purpura: does it really work?","volume":"163","author":"Russo","year":"2004","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib102","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib103","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2004.09.004","article-title":"Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment","volume":"146","author":"Wang","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib106","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib107","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib108","first-page":"281","article-title":"Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood","volume":"90","author":"Taube","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib109","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00277-006-0123-3","article-title":"Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients","volume":"85","author":"Penalver","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib110","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2006-01-0197","article-title":"Putting the \u201dTux\u201d on ITP","volume":"107","author":"Cines","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib111","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib112","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib113","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib114","first-page":"79","article-title":"Rituximab in indolent lymphoma: the single-agent pivotal trial","volume":"26","author":"McLaughlin","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib116","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajh.20135","article-title":"Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)","volume":"77","author":"Swords","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib117","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1056\/NEJM200306263482619","article-title":"Interstitial pneumonitis related to rituximab therapy","volume":"348","author":"Burton","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib118","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"van der Kolk","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib119","first-page":"113","article-title":"Rituximab in autoimmune cytopenias: for which patients?","volume":"87","author":"Finazzi","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jpeds.2005.04.045","article-title":"Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children","volume":"147","author":"Cesaro","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib121","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib122","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib123","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/10428190500052347","article-title":"Granulocyte colony-stimulating factor (G-CSF) could enhance Fcgamma receptor expression in neutrophils of patients with B-cell lymphoma treated with rituximab","volume":"46","author":"Sashida","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib124","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib125","doi-asserted-by":"crossref","first-page":"iv77","DOI":"10.1136\/ard.2005.042507","article-title":"How does B cell depletion therapy work, and how can it be improved?","volume":"64","author":"Clark","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib126","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib127","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects","volume":"100","author":"Rose","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/107602960601200116","article-title":"Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review","volume":"12","author":"Perrotta","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib129","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hci130","article-title":"Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura","volume":"98","author":"Perez-Calvo","year":"2005","journal-title":"QJM"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib130","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1517\/14656566.5.12.2515","article-title":"Immune thrombocytopenic purpura\u2014current management practices","volume":"5","author":"Sandler","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib131","doi-asserted-by":"crossref","unstructured":"The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997;126:319\u201326.","DOI":"10.7326\/0003-4819-126-4-199702150-00010"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib132","first-page":"49a","article-title":"Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura","volume":"94","author":"Perotta","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib133","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","article-title":"Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura","volume":"99","author":"Stasi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.06.007_bib134","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4065\/78.11.1340","article-title":"Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome","volume":"78","author":"Shanafelt","year":"2003","journal-title":"Mayo Clin Proc"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:26:39Z","timestamp":1760901999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842807001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1040842807001205"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2007.06.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2007.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}